Please login to the form below

Not currently logged in
Email:
Password:

Inovio

This page shows the latest Inovio news and features for those working in and with pharma, biotech and healthcare.

Inovio plans late-stage COVID-19 vaccine study in second quarter 2021

Inovio plans late-stage COVID-19 vaccine study in second quarter 2021

On Monday, Inovio also announced that it has signed a collaboration and licence agreement for INO-4800 with Chinese biotech Advaccine Biopharmaceuticals Suzhou. ... Inovio and Advaccine are already working together on the clinical development of INO-4800

Latest news

  • Inovio hit with FDA hold on COVID-19 vaccine trial Inovio hit with FDA hold on COVID-19 vaccine trial

    The US Food and Drug Administration (FDA) has placed a temporary hold on Inovio Pharmaceuticals’ mid-to-late stage coronavirus vaccine trial. ... Importantly, the clinical hold is not due to the occurrence of any adverse events related to the vaccine,

  • CEPI says $2bn is needed for COVID-19 vaccine development CEPI says $2bn is needed for COVID-19 vaccine development

    CEPI has already invested $4.4m in partnering agreements with Novavax and The University of Oxford to rapidly develop COVID-19 vaccine candidates, and it also announced initial funding to Inovio

  • Trial backs Inovio/Sanofi combo in hard-to-treat brain cancer Trial backs Inovio/Sanofi combo in hard-to-treat brain cancer

    Results at six months demonstrated 75% of patients were progression-free. A combination of three cancer immunotherapy drugs from Inovio and Sanofi/Regeneron has shown impressive results in glioblastoma multiforme (GBM), ... Newly-diagnosed GBM patients

  • Takeda gets FDA fast-track status for Zika vaccine Takeda gets FDA fast-track status for Zika vaccine

    Last year Inovio Pharma and GeneOne Life Sciences reported phase I data with their synthetic GLS-5700 DNA vaccine in the New England Journal of Medicine (NEJM), concluding that it was

  • AZ adds cancer vaccine to immuno-oncology portfolio AZ adds cancer vaccine to immuno-oncology portfolio

    AstraZeneca has signed a strategic-level licensing deal with Inovio for cancer vaccines that flesh out its cancer immunotherapy pipeline. ... The result is what Inovio claims is a 'best-in-class' T cell-stimulating therapy, generating fully functional

More from news
Approximately 4 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • COVID-19: the race to find a vaccine COVID-19: the race to find a vaccine

    Inovio Pharmaceuticals began testing its plasmid candidate in humans in April, putting it at the head of a pack of six groups that have DNA vaccines in development.

  • Developing a COVID-19 vaccine Developing a COVID-19 vaccine

    The CEPI has currently initiated eight COVID-19 vaccine developments with Curevac, Inovio Pharmaceuticals, Moderna, Novavax, The University of Hong Kong, The University of Oxford, The University of Queensland and a

  • Deal Watch February 2017 Deal Watch February 2017

    Amendment to 2015 agreement. 80. Inovio Pharmaceuticals/ ApolloBio Corporation. VGX-3100, DNA immunotherapy to treat pre-cancers caused by human papillomavirus (phase II).

  • Pharma deals in August 2015 Pharma deals in August 2015

    AstraZeneca deals. Subject. Headline $m. Inovio. Cancer vaccines. 727. Heptares. HTL 1071 and A2A receptor blocking compounds. ... Acquisition ‐ company. 847. Inovio. AZ/Medimmune. INO‐3112 vaccine in P1/2 for cervical and head &neck cancer.

  • Deal Watch table for September 2013 Deal Watch table for September 2013

    483. BioFire Diagnostics / BioMerieux. Acquisition. Invitro diagnostic company. 450. Inovio Pharma / Roche Holdings.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
M3 (EU)

M3 has over 20 years’ experience in building online doctor communities. M3 is the world’s largest network of verified doctors...

Latest intelligence

The communication challenge of helping he next generation to be healthier
As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
Are we losing sight of what the democratisation of healthcare really looks like?
We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
William Kilgallon
How the Royal Society’s EiR programme can help to drive UK innovation
...